PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

ENCORE: Early ALIS Cuts MACLD Recurrence, With Jakko Van Ingen, MD, PhD

Sep 21, 2026 · 0:09:52
Listen to Episode
✨ AI Summary
  • Early amikacin liposome inhalation (ALIS) cuts MACLD recurrence.
  • Over 40% of patients fail standard multidrug therapy for MACLD.
  • Jakko van Ingen, MD, PhD, presented ENCORE trial data.

Guests on This Episode

JI
Jakko Van Ingen
researcher · 2 podcast appearances
›

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →